LABU Direxion Daily S&P Biotech Bull 3X Shares
Kurs vom Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Vorheriger Schlusskurs | 223.00 | Tagesspanne | 223.71 – 246.22 |
| 52-Wochen-Spanne | 102.35 – 341.93 | Volumen | 605.18K |
| Durchschn. Volumen | 473.54K | AUM | $597.1M (Oct 10, 2026) |
| Kostenquote | 0.96% | Rendite (TTM) | 0.37% |
| NAV | 223.27 | Aufgeld/Abschlag | +8.88% indikativ |
| Auflegung | May 28, 2015 | Positionen | 156 |
| Anbieter | Direxion | Börse | AMEX |
| Kategorie | Biotech | Abgebildeter Index | In den Quelldaten nicht angegeben |
| CUSIP | 25460G120 | ISIN | US25460G1206 |
| Struktur | Gehebelt 3x | ||
| Management | Passiv / indexnachbildend (laut Emittentenbeschreibung) | ||
Über diesen ETF
Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF is an exchange traded fund launched by Direxion Investments. It is managed by Rafferty Asset Management, LLC. It invests in public equity markets of the United States. It invests directly, through derivatives and through other funds in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. It uses derivatives such as futures, swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track 3x the daily performance of the S&P Biotechnology Select Industry Index. Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF was formed on May 28, 2015 and is domiciled in the United States.
Beschreibung vom Fondsdatenanbieter · Profil per Oct 10, 2026.
Kurschart
Tägliche Schlusskurse (Kursrendite, nicht Gesamtrendite). Die Vergleichslinien sind auf die prozentuale Veränderung ab dem Beginn des Zeitraums normiert. Quelle: Financial Modeling Prep.
Wertentwicklung
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Auflegung* | |
|---|---|---|---|---|---|---|---|---|---|
| Kursrendite | -12.88% | -17.27% | +40.80% | +52.51% | +117.01% | +49.92% | -25.24% | -11.78% | -20.14% |
| Gesamtrendite | -12.88% | -17.27% | +40.80% | +52.51% | +118.14% | +50.74% | -24.97% | -11.54% | -19.95% |
* Annualisiert. Die Gesamtrendite verwendet die dividendenbereinigte Kursreihe (Ausschüttungen reinvestiert); die Kursrendite verwendet unbereinigte Schlusskurse. Wertentwicklung per Oct 09, 2026. Vergangene Wertentwicklungen sind kein verlässlicher Indikator für künftige Ergebnisse.
Gebühren
| Nettokostenquote | 0.96% | Jährliche Kosten einer Anlage von 10.000 $ | $96.00 |
Nur zur Veranschaulichung: Kostenquote × 10.000 $. Handelskosten, Geld-Brief-Spannen, Steuern und Wertänderungen sind nicht enthalten. Details zu Brutto- und Nettokostenquote sowie etwaige Gebührenbefreiungen sind im Prospekt aufgeführt.
Positionen
Positionen per Oct 10, 2026 · Portfolio-Meldedatum des Datenanbieters; die Positionen sind keine Echtzeit-Bestände. 173 Zeilen in der Datenbank.
| # | Position | Ticker | Gewichtung | Aktien | Marktwert |
|---|---|---|---|---|---|
| 1 | SPSIBI SWAP ASSET LEG (SPSIBICTL) | — | 15.92% | 26.46K | $309.3M |
| 2 | SPSIBI SWAP ASSET LEG (SPSIBIUBL) | — | 15.47% | 25.72K | $300.6M |
| 3 | SPSIBI SWAP ASSET LEG (SPSIBIMLL) | — | 14.09% | 23.42K | $273.8M |
| 4 | SPSIBI SWAP ASSET LEG (SPSIBIBCL) | — | 11.19% | 18.60K | $217.4M |
| 5 | SPSIBI SWAP ASSET LEG (SPSIBIJPL) | — | 9.48% | 15.77K | $184.3M |
| 6 | GOLDMAN FINL SQ TRSRY INST 506 | — | 6.66% | 129.34M | $129.3M |
| 7 | SPSIBI SWAP ASSET LEG (SPSIBIBPL) | — | 1.28% | 2.13K | $24.9M |
| 8 | DREYFUS GOVT CASH MAN INS | — | 1.04% | 20.25M | $20.3M |
| 9 | SPSIBI SWAP ASSET LEG (SPSIBIGSL) | — | 0.83% | 1.39K | $16.2M |
| 10 | MODERNA INC | MRNA | 0.53% | 52.01K | $10.2M |
| 11 | TWIST BIOSCIENCE CORP | TWST | 0.44% | 56.19K | $8.5M |
| 12 | NATERA INC | NTRA | 0.43% | 21.35K | $8.3M |
| 13 | ABBVIE INC | ABBV | 0.39% | 28.11K | $7.7M |
| 14 | UNITED THERAPEUTICS CORP | UTHR | 0.38% | 13.91K | $7.4M |
| 15 | AMGEN INC | AMGN | 0.38% | 18.02K | $7.3M |
| 16 | BIOGEN INC | BIIB | 0.38% | 33.47K | $7.3M |
| 17 | HALOZYME THERAPEUTICS INC | HALO | 0.37% | 65.67K | $7.2M |
| 18 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 0.37% | 536.96K | $7.1M |
| 19 | EXELIXIS INC | EXEL | 0.37% | 120.91K | $7.1M |
| 20 | GILEAD SCIENCES INC | GILD | 0.37% | 48.42K | $7.1M |
| 21 | TG THERAPEUTICS INC | TGTX | 0.35% | 129.05K | $6.9M |
| 22 | VERTEX PHARMACEUTICALS INC | VRTX | 0.35% | 13.53K | $6.8M |
| 23 | PROTAGONIST THERAPEUTICS INC | PTGX | 0.35% | 48.38K | $6.8M |
| 24 | KRYSTAL BIOTECH INC | KRYS | 0.34% | 20.26K | $6.6M |
| 25 | CRISPR THERAPEUTICS AG | CRSP | 0.34% | 129.65K | $6.5M |
| 26 | PTC THERAPEUTICS INC | PTCT | 0.34% | 104.37K | $6.5M |
| 27 | SPYRE THERAPEUTICS INC | SYRE | 0.33% | 81.13K | $6.5M |
| 28 | REGENERON PHARMACEUTICALS | REGN | 0.33% | 8.73K | $6.5M |
| 29 | NEUROCRINE BIOSCIENCES INC | NBIX | 0.33% | 45.46K | $6.4M |
| 30 | REVOLUTION MEDICINES INC | RVMD | 0.33% | 33.96K | $6.4M |
| 31 | INCYTE CORP | INCY | 0.32% | 55.97K | $6.3M |
| 32 | ALKERMES PLC | ALKS | 0.32% | 155.35K | $6.2M |
| 33 | GRAIL INC | GRAL | 0.32% | 46.93K | $6.2M |
| 34 | ERASCA INC | ERAS | 0.32% | 400.00K | $6.2M |
| 35 | VAXCYTE INC | PCVX | 0.32% | 94.99K | $6.2M |
| 36 | MADRIGAL PHARMACEUTICALS INC | MDGL | 0.32% | 12.90K | $6.2M |
| 37 | ALNYLAM PHARMACEUTICALS INC | ALNY | 0.32% | 27.34K | $6.1M |
| 38 | BRIDGEBIO PHARMA INC | BBIO | 0.31% | 92.70K | $6.0M |
| 39 | BIOMARIN PHARMACEUTICAL INC | BMRN | 0.31% | 109.50K | $6.0M |
| 40 | ORUKA THERAPEUTICS INC | ORKA | 0.31% | 77.08K | $6.0M |
| 41 | CYTOKINETICS INC | CYTK | 0.30% | 95.16K | $5.9M |
| 42 | KODIAK SCIENCES INC | KOD | 0.30% | 61.43K | $5.8M |
| 43 | ROIVANT SCIENCES LTD | ROIV | 0.30% | 168.68K | $5.8M |
| 44 | COGENT BIOSCIENCES INC | COGT | 0.29% | 186.18K | $5.6M |
| 45 | KYMERA THERAPEUTICS INC | KYMR | 0.29% | 51.07K | $5.6M |
| 46 | TRAVERE THERAPEUTICS INC | TVTX | 0.29% | 106.50K | $5.5M |
| 47 | IMMUNITYBIO INC | IBRX | 0.28% | 558.48K | $5.5M |
| 48 | INSMED INC | INSM | 0.28% | 54.76K | $5.5M |
| 49 | IONIS PHARMACEUTICALS INC | IONS | 0.28% | 125.89K | $5.5M |
| 50 | DIANTHUS THERAPEUTICS INC | DNTH | 0.28% | 65.89K | $5.4M |
| 51 | PRAXIS PRECISION MEDICINES I | PRAX | 0.28% | 20.43K | $5.4M |
| 52 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 0.27% | 85.36K | $5.2M |
| 53 | RHYTHM PHARMACEUTICALS INC | RYTM | 0.26% | 56.53K | $5.1M |
| 54 | VERACYTE INC | VCYT | 0.25% | 111.30K | $4.9M |
| 55 | MIRUM PHARMACEUTICALS INC | MIRM | 0.25% | 58.66K | $4.8M |
| 56 | CG ONCOLOGY INC | CGON | 0.24% | 73.58K | $4.7M |
| 57 | VIKING THERAPEUTICS INC | VKTX | 0.23% | 164.40K | $4.6M |
| 58 | TANGO THERAPEUTICS INC | TNGX | 0.23% | 194.01K | $4.4M |
| 59 | RELAY THERAPEUTICS INC | RLAY | 0.21% | 232.09K | $4.0M |
| 60 | BEAM THERAPEUTICS INC | BEAM | 0.21% | 164.23K | $4.0M |
| 61 | CAREDX INC | CDNA | 0.20% | 63.31K | $3.9M |
| 62 | CELCUITY INC | CELC | 0.20% | 57.13K | $3.9M |
| 63 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 0.19% | 244.18K | $3.7M |
| 64 | SCHOLAR ROCK HOLDING CORP | SRRK | 0.19% | 87.01K | $3.7M |
| 65 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 0.18% | 144.72K | $3.5M |
| 66 | DYNE THERAPEUTICS INC | DYN | 0.18% | 208.42K | $3.4M |
| 67 | HYPERLIQUID STRATEGIES | PURR | 0.17% | 287.13K | $3.2M |
| 68 | RECURSION PHARMACEUTICALS-A | RXRX | 0.16% | 795.95K | $3.1M |
| 69 | SELLAS LIFE SCIENCES GROUP I | SLS | 0.16% | 271.50K | $3.1M |
| 70 | IMMUNOVANT INC | IMVT | 0.16% | 100.97K | $3.1M |
| 71 | SUMMIT THERAPEUTICS INC | SMMT | 0.15% | 174.18K | $3.0M |
| 72 | IDEAYA BIOSCIENCES INC | IDYA | 0.14% | 76.03K | $2.7M |
| 73 | BIOCRYST PHARMACEUTICALS INC | BCRX | 0.14% | 330.21K | $2.7M |
| 74 | DENALI THERAPEUTICS INC | DNLI | 0.14% | 146.40K | $2.7M |
| 75 | VERA THERAPEUTICS INC | VERA | 0.13% | 87.90K | $2.6M |
| 76 | AGIOS PHARMACEUTICALS INC | AGIO | 0.13% | 81.63K | $2.6M |
| 77 | INTELLIA THERAPEUTICS INC | NTLA | 0.13% | 205.40K | $2.6M |
| 78 | SAREPTA THERAPEUTICS INC | SRPT | 0.13% | 141.82K | $2.6M |
| 79 | NOVAVAX INC | NVAX | 0.12% | 220.60K | $2.4M |
| 80 | ARCUS BIOSCIENCES INC | RCUS | 0.12% | 99.24K | $2.4M |
| 81 | NURIX THERAPEUTICS INC | NRIX | 0.12% | 105.06K | $2.3M |
| 82 | ACADIA PHARMACEUTICALS INC | ACAD | 0.12% | 118.48K | $2.3M |
| 83 | PALVELLA THERAPEUTICS INC | PVLA | 0.12% | 17.36K | $2.3M |
| 84 | CELLDEX THERAPEUTICS INC | CLDX | 0.12% | 76.82K | $2.3M |
| 85 | ADMA BIOLOGICS INC | ADMA | 0.12% | 217.26K | $2.2M |
| 86 | VIRIDIAN THERAPEUTICS INC | VRDN | 0.11% | 119.57K | $2.2M |
| 87 | UNIQURE NV | QURE | 0.11% | 96.96K | $2.2M |
| 88 | ABSCI CORP | ABSI | 0.11% | 237.02K | $2.1M |
| 89 | VERICEL CORP | VCEL | 0.11% | 52.88K | $2.1M |
| 90 | BIOHAVEN LTD | BHVN | 0.11% | 177.26K | $2.1M |
| 91 | DISC MEDICINE INC | IRON | 0.11% | 34.49K | $2.1M |
| 92 | PRECIGEN INC | PGEN | 0.11% | 271.88K | $2.1M |
| 93 | SYNDAX PHARMACEUTICALS INC | SNDX | 0.11% | 122.06K | $2.1M |
| 94 | NEKTAR THERAPEUTICS | NKTR | 0.10% | 46.73K | $1.9M |
| 95 | GOLDMAN SACHS FIN GOV 465 INSTITUT | — | 0.10% | 1.89M | $1.9M |
| 96 | IMMUNOME INC | IMNM | 0.09% | 93.50K | $1.8M |
| 97 | MINERALYS THERAPEUTICS INC | MLYS | 0.08% | 70.38K | $1.6M |
| 98 | REPLIMUNE GROUP INC | REPL | 0.08% | 119.22K | $1.6M |
| 99 | XENCOR INC | XNCR | 0.08% | 62.48K | $1.5M |
| 100 | STOKE THERAPEUTICS INC | STOK | 0.08% | 62.85K | $1.5M |
| 101 | INHIBRX BIOSCIENCES INC | INBX | 0.07% | 15.56K | $1.4M |
| 102 | ANAPTYSBIO INC | ANAB | 0.07% | 30.69K | $1.4M |
| 103 | ORIC PHARMACEUTICALS INC | ORIC | 0.07% | 115.85K | $1.4M |
| 104 | VIR BIOTECHNOLOGY INC | VIR | 0.07% | 122.00K | $1.4M |
| 105 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 0.07% | 41.89K | $1.3M |
| 106 | ZENAS BIOPHARMA INC | ZBIO | 0.07% | 49.72K | $1.3M |
| 107 | KURA ONCOLOGY INC | KURA | 0.07% | 121.78K | $1.3M |
| 108 | MANNKIND CORP | MNKD | 0.06% | 343.38K | $1.2M |
| 109 | JADE BIOSCIENCES INC | JBIO | 0.06% | 82.17K | $1.2M |
| 110 | ARDELYX INC | ARDX | 0.06% | 348.49K | $1.1M |
| 111 | ANNEXON INC | ANNX | 0.06% | 280.20K | $1.1M |
| 112 | RIGEL PHARMACEUTICALS INC | RIGL | 0.06% | 22.70K | $1.1M |
| 113 | TYRA BIOSCIENCES INC | TYRA | 0.06% | 55.34K | $1.1M |
| 114 | TAYSHA GENE THERAPIES INC | TSHA | 0.06% | 246.24K | $1.1M |
| 115 | GERON CORP | GERN | 0.05% | 865.19K | $1.1M |
| 116 | MONTE ROSA THERAPEUTICS INC | GLUE | 0.05% | 100.83K | $1.0M |
| 117 | CANDEL THERAPEUTICS INC | CADL | 0.05% | 104.44K | $1.0M |
| 118 | JANUX THERAPEUTICS INC | JANX | 0.05% | 54.36K | $1.0M |
| 119 | VOR BIOPHARMA INC | VOR | 0.05% | 52.30K | $1.0M |
| 120 | AVALO THERAPEUTICS INC | AVTX | 0.05% | 70.47K | $946.4K |
| 121 | IMMIX BIOPHARMA INC | IMMX | 0.05% | 98.58K | $915.8K |
| 122 | CULLINAN THERAPEUTICS INC | CGEM | 0.05% | 58.76K | $908.5K |
| 123 | BICARA THERAPEUTICS INC | BCAX | 0.05% | 52.16K | $900.3K |
| 124 | CORVUS PHARMACEUTICALS INC | CRVS | 0.05% | 86.81K | $886.3K |
| 125 | VERASTEM INC | VSTM | 0.04% | 107.67K | $873.2K |
| 126 | OLEMA PHARMACEUTICALS INC | OLMA | 0.04% | 102.79K | $803.8K |
| 127 | REGENXBIO INC | RGNX | 0.04% | 94.93K | $768.0K |
| 128 | HEMAB THERAPEUTICS HOLDINGS | COAG | 0.04% | 24.67K | $762.1K |
| 129 | ARRIVENT BIOPHARMA INC | AVBP | 0.04% | 44.02K | $735.6K |
| 130 | SAVARA INC | SVRA | 0.04% | 152.25K | $735.4K |
| 131 | SANA BIOTECHNOLOGY INC | SANA | 0.04% | 261.73K | $730.2K |
| 132 | ACHIEVE LIFE SCIENCES INC | ACHV | 0.04% | 100.42K | $722.0K |
| 133 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 0.04% | 56.30K | $715.0K |
| 134 | DAMORA THERAPEUTICS INC | — | 0.04% | 34.67K | $712.9K |
| 135 | CAPRICOR THERAPEUTICS INC | CAPR | 0.04% | 85.27K | $683.0K |
| 136 | ALLOGENE THERAPEUTICS INC | ALLO | 0.03% | 443.61K | $621.1K |
| 137 | PRIME MEDICINE INC | PRME | 0.03% | 173.37K | $620.7K |
| 138 | IRONWOOD PHARMACEUTICALS INC | IRWD | 0.03% | 159.13K | $615.8K |
| 139 | CYTOMX THERAPEUTICS INC | CTMX | 0.03% | 243.27K | $600.9K |
| 140 | KAILERA THERAPEUTICS INC | KLRA | 0.03% | 58.55K | $585.5K |
| 141 | EDITAS MEDICINE INC | EDIT | 0.03% | 202.66K | $575.6K |
| 142 | SOLID BIOSCIENCES INC | SLDB | 0.03% | 83.85K | $571.9K |
| 143 | MYRIAD GENETICS INC | MYGN | 0.03% | 135.74K | $570.1K |
| 144 | CLIMB BIO INC | CLYM | 0.03% | 51.57K | $560.0K |
| 145 | ARBUTUS BIOPHARMA CORP | ABUS | 0.03% | 133.82K | $559.4K |
| 146 | ALTIMMUNE INC | ALT | 0.03% | 213.26K | $554.5K |
| 147 | MONOPAR THERAPEUTICS INC | MNPR | 0.03% | 6.58K | $552.4K |
| 148 | SAGIMET BIOSCIENCES INC-A | SGMT | 0.03% | 60.53K | $540.0K |
| 149 | EMERGENT BIOSOLUTIONS INC | EBS | 0.03% | 77.41K | $527.2K |
| 150 | DESIGN THERAPEUTICS INC | DSGN | 0.03% | 44.78K | $514.6K |
| 151 | OCUGEN INC | OCGN | 0.03% | 518.94K | $507.2K |
| 152 | SHATTUCK LABS INC | STTK | 0.03% | 87.80K | $496.9K |
| 153 | ARS PHARMACEUTICALS INC | SPRY | 0.02% | 104.26K | $475.4K |
| 154 | CABALETTA BIO INC | CABA | 0.02% | 236.91K | $462.0K |
| 155 | AKTIS ONCOLOGY INC | AKTS | 0.02% | 24.43K | $433.4K |
| 156 | MIMEDX GROUP INC | MDXG | 0.02% | 86.22K | $398.4K |
| 157 | VANDA PHARMACEUTICALS INC | VNDA | 0.02% | 85.71K | $388.3K |
| 158 | PROTHENA CORP PLC | PRTA | 0.02% | 43.33K | $373.1K |
| 159 | NEUROGENE INC | NGNE | 0.02% | 12.79K | $339.0K |
| 160 | ASSEMBLY BIOSCIENCES INC | ASMB | 0.02% | 14.46K | $329.9K |
| 161 | OVID THERAPEUTICS INC | OVID | 0.02% | 133.00K | $311.2K |
| 162 | AURA BIOSCIENCES INC | AURA | 0.02% | 44.95K | $292.4K |
| 163 | FAETH THERAPEUTICS INC | FTH | 0.01% | 10.27K | $263.1K |
| 164 | LEXEO THERAPEUTICS INC | LXEO | 0.01% | 75.81K | $243.3K |
| 165 | DREYFUS TRSRY SECURITIES CASH MGMT | — | 0.01% | 240.95K | $240.9K |
| 166 | COMPASS THERAPEUTICS INC | CMPX | 0.01% | 230.39K | $226.6K |
| 167 | CRESCENT BIOPHARMA INC | CBIO | 0.01% | 15.93K | $225.0K |
| 168 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 0.01% | 31.55K | $107.9K |
| 169 | INHIBRX INC CVR | — | 0.00% | 164.17K | $0.00 |
| 170 | OMNIAB INC - 15.00 EARNOUT | 2200964 | 0.00% | 14.78K | $0.00 |
| 171 | NOVOB DC CVR | — | 0.00% | 128.72K | $0.00 |
| 172 | VERVE THERAPEUTICS INC (CVR) | — | 0.00% | 82.53K | $0.00 |
| 173 | OMNIAB INC - 12.5 EARNOUT | 2200963 | 0.00% | 14.78K | $0.00 |
Auf einen Ticker klicken, um alle ETFs anzuzeigen, die ihn halten.
Sektorgewichtung
Geografisches Exposure
Ländergewichtungen gemäß Angaben des Datenanbieters. Die Einstufung als Industrieland/Schwellenland/Frontier-Markt folgt der Klassifikation auf der Methodikseite. Währungsgesichert: Kein Währungshedging im Fondsnamen angegeben.
Ausschüttungen
| Rendite (TTM) | 0.37% | Ausgeschüttet (letzte 12 Monate) | $0.9097 |
| Frequenz | Quarterly | SEC-Rendite | Von unserer Datenquelle nicht bereitgestellt; siehe Emittentenseite |
| Letztes Ex-Datum | Dec 23, 2025 | Letzte Ausschüttung | $0.9097 (Dec 31, 2025) |
| Wachstum 1J | +112.13% | Wachstum 3J / 5J (ann.) | +335.68% / — |
| Ex-Datum | Stichtag | Zahltag | Betrag |
|---|---|---|---|
| Dec 23, 2025 | Dec 23, 2025 | Dec 31, 2025 | $0.9097 |
| Sep 23, 2025 | Sep 23, 2025 | Sep 30, 2025 | $0.1027 |
| Jun 24, 2025 | Jun 24, 2025 | Jul 01, 2025 | $0.2190 |
| Mar 25, 2025 | Mar 25, 2025 | Apr 01, 2025 | $0.1071 |
| Jun 25, 2024 | Jun 25, 2024 | Jul 02, 2024 | $0.1502 |
| Mar 19, 2024 | Mar 20, 2024 | Mar 26, 2024 | $0.1606 |
| Dec 21, 2023 | Dec 22, 2023 | Dec 29, 2023 | $0.2097 |
| Sep 19, 2023 | Sep 20, 2023 | Sep 26, 2023 | $0.0020 |
| Jun 21, 2023 | Jun 22, 2023 | Jun 28, 2023 | $0.0090 |
| Dec 23, 2019 | Dec 24, 2019 | Dec 31, 2019 | $0.0050 |
| Sep 24, 2019 | Sep 25, 2019 | Oct 01, 2019 | $0.0110 |
| Jun 25, 2019 | Jun 26, 2019 | Jul 02, 2019 | $0.0370 |
Nachlaufende Ausschüttungsrendite = Ausschüttungen der letzten 12 Monate ÷ aktueller Kurs. Dies ist NICHT die SEC-30-Tage-Rendite, und künftige Ausschüttungen sind nicht garantiert. Der Unterschied erklärt →
Risikokennzahlen
| Volatilität 1J / 3J | 85.18% / 83.94% | Sharpe 1J / 3J | 2.63 / 1.34 |
| Maximaler Drawdown 1J / 3J | -34.71% / -78.30% | Sortino 1J | 4.10 |
| Beta gegenüber S&P 500 (3J) | 3.06 | Korrelation vs. S&P 500 (1J) | 0.436 |
| Abwärtsabweichung 1J | 54.71% | Verwendeter risikofreier Zinssatz | 4.05% (3M T-bill, FRED) |
Berechnet von ETF Explorer Berechnet aus täglichen dividendenbereinigten Schlusskursen; Volatilität und Drawdown sind annualisierte Werte bzw. Periodenwerte; S&P-500-Exposure wird durch SPY approximiert. Stand Oct 11, 2026. Formeln →
Liquidität
| Heutiges Volumen | 605.18K | Durchschnittliches Volumen | 473.54K |
| AUM | $597.1M | Aufgeld/Abschlag | +8.88% |
| Geld-/Briefspanne | Von unserer Datenquelle nicht bereitgestellt. Prüfen Sie den Kursbildschirm Ihres Brokers; die Spreads sind zur Eröffnung und zum Börsenschluss am weitesten. | ||
Aufgeld/Abgeld vergleicht den verzögerten Marktpreis mit dem zuletzt gemeldeten NAV: ein indikativerer Wert, nicht das offizielle Schlussaufgeld/-abgeld. So funktioniert die ETF-Liquidität →
Fondsflüsse (geschätzt)
| Zeitraum | Gesch. Nettomittelfluss | % des anfänglichen AUM | AUM Anfang → Ende |
|---|---|---|---|
| 1 Tag | $9.4K | 0.00% | $597.1M → $597.1M |
| 1 Monat | $111.2M | +21.29% | $522.3M → $597.1M |
| 1 Woche | $19.6M | +3.31% | $590.9M → $597.1M |
ETF-Explorer-Schätzung: Veränderung des gemeldeten AUM abzüglich des Marktbewegungseffekts, basierend auf unseren eigenen täglichen Momentaufnahmen. Keine offiziellen Ausgabe-/Rücknahmezahlen des Emittenten.
Offizielle Fondsressourcen
Externe Links öffnen die Website des Emittenten oder SEC EDGAR in einem neuen Tab. Der Prospekt und die offiziellen Dokumente sind stets die maßgebliche Quelle; bitte prüfen Sie diese vor einer Anlageentscheidung.
Aktuelle Nachrichten zu LABU
In den letzten 7 Tagen erwähnt kein Artikel diesen Fonds direkt; es wird allgemeine ETF-Berichterstattung angezeigt.
Erklärung: AUM ist das Fondsvermögen. Die Kostenquote (Expense Ratio) ist der jährliche Kostensatz, der bereits in der Rendite berücksichtigt ist. Der NAV ist der Wert des Fondsvermögens je Anteil; der Marktpreis kann leicht darüber (Aufgeld) oder darunter (Abgeld) liegen. Die Gesamtrendite setzt voraus, dass Ausschüttungen reinvestiert wurden. Jeder Datensatz zeigt sein eigenes Stichtagsdatum, da Bestände, Vermögen und Kurse nach unterschiedlichen Zeitplänen aktualisiert werden.